How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,541 results for

Pharmaceutical Representative

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Ending pharmaceutical sales representatives' access to hospitals and students

Ending pharmaceutical sales representatives' access to hospitals and students Prescrire IN ENGLISH - Spotlight ''Ending pharmaceutical sales representatives' access to hospitals and students'', 1 November 2018 {1} {1} {1} | | > > > Ending pharmaceutical sales representatives' access to hospitals and students Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  (...) Spotlight In the November issue of Prescrire International: Ending pharmaceutical sales representatives' access to hospitals and students FREE DOWNLOAD In-person promotion of drugs to healthcare professionals by pharmaceutical sales representatives, known as pharmaceutical detailing, has been shown to influence doctors' prescribing behaviour. A US study looked at ways to limit this influence. Full text available for free download. Summary A large-scale case-control study has evaluated policies

2018 Prescrire

2. Becoming a ‘pharmaceutical person’: Medication use trajectories from age 26 to 38 in a representative birth cohort from Dunedin, New Zealand (PubMed)

Becoming a ‘pharmaceutical person’: Medication use trajectories from age 26 to 38 in a representative birth cohort from Dunedin, New Zealand Despite the abundance of medications available for human consumption, and frequent concerns about increasing medicalization or pharmaceuticalization of everyday life, there is little research investigating medicines-use in young and middle-aged populations and discussing the implications of young people using increasing numbers of medicines (...) and becoming pharmaceutical users over time. We use data from a New Zealand longitudinal study to examine changes in self-reported medication use by a complete birth cohort of young adults. Details of medications taken during the previous two weeks at age 38 are compared to similar data collected at ages 32 and 26, and by gender. Major drug categories are examined. General use profiles and medicine-types are considered in light of our interest in understanding the formation of the young and middle-aging

Full Text available with Trip Pro

2017 SSM - population health

3. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. (PubMed)

Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on posttraining attitudes and behavior. The long-term effect of policies restricting contact between residents and pharmaceutical company representatives (PCRs) during internal medicine training is unknown. The McMaster University Department of Medicine in Hamilton, Ontario, implemented a policy restricting PCR contact with trainees in 1992, whereas the Department of Medicine

2017 JAMA

4. Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies; Commentary: dramaturgical model gives valuable insight. (PubMed)

Dramaturgical study of meetings between general practitioners and representatives of pharmaceutical companies; Commentary: dramaturgical model gives valuable insight. To examine the interaction between general practitioners and pharmaceutical company representatives.Qualitative study of 13 consecutive meetings between general practitioner and pharmaceutical representatives. A dramaturgical model was used to inform analysis of the transcribed verbal interactions.Practice in south west England.13 (...) pharmaceutical company representatives and one general practitioner.The encounters were acted out in six scenes. Scene 1 was initiated by the pharmaceutical representative, who acknowledged the relative status of the two players. Scene 2 provided the opportunity for the representative to check the general practitioner's knowledge about the product. Scene 3 was used to propose clinical and cost benefits associated with the product. During scene 4, the general practitioner took centre stage and challenged

Full Text available with Trip Pro

2017 BMJ

5. Can e-Cigarettes and Pharmaceutical Aids Increase Smoking Cessation and Reduce Cigarette Consumption? Findings from a Nationally Representative Cohort of American Smokers. (PubMed)

Can e-Cigarettes and Pharmaceutical Aids Increase Smoking Cessation and Reduce Cigarette Consumption? Findings from a Nationally Representative Cohort of American Smokers. Many smokers believe that electronic nicotine delivery systems (ENDS) and pharmaceutical cessation aids can help them quit smoking or reduce cigarette consumption, but the evidence for e-cigarettes to aid quitting is limited. Examining 3,093 quit attempters in the nationally representative US Population Assessment of Tobacco (...) and Health (PATH) Study, using data from 2013-2015, we evaluated the influence of ENDS and pharmaceutical cessation aids on persistent abstinence (≥30 days) from cigarettes and reduced cigarette consumption, using propensity score matching to balance comparison groups on potential confounders and multiple imputation to handle missing data. At PATH Wave 2, 25.2% of quit attempters reported using ENDS to quit during the previous year, making it the most popular cessation aid in 2014-2015. More quit

2018 American Journal of Epidemiology

6. RE: Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers (PubMed)

RE: Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers 29506226 2018 11 14 1460-2105 110 10 2018 Oct 01 Journal of the National Cancer Institute J. Natl. Cancer Inst. RE: Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers. 1141 10.1093/jnci/djy025 Shiffman Saul S Pinney Associates, Pittsburgh, PA. University of Pittsburgh, Pittsburgh, PA. Gitchell Joe G JG Pinney

Full Text available with Trip Pro

2018 JNCI Journal of the National Cancer Institute

7. Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers. (PubMed)

Effectiveness of Pharmaceutical Smoking Cessation Aids in a Nationally Representative Cohort of American Smokers. Despite strong efficacy in randomized trials, the population effectiveness of pharmaceutical aids in long-term smoking cessation is lacking, possibly because of confounding (factors that are associated with both pharmaceutical aid use and difficulty quitting). Matching techniques in longitudinal studies can remove this confounding bias.Using the nationally representative Tobacco Use (...) Supplement to the Current Population Survey (TUS-CPS), we assessed the effectiveness of medications to aid quitting among baseline adult smokers who attempted to quit prior to one year of follow-up in two longitudinal studies: 2002-2003 and 2010-2011. Pharmaceutical aid users and nonusers with complete data (n = 2129) were matched using propensity score models with 12 potential confounders (age, sex, race-ethnicity, education, smoking intensity, nicotine dependence, previous quit history, self-efficacy

Full Text available with Trip Pro

2017 Journal of the National Cancer Institute

8. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review. (PubMed)

Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: a systematic review. The objective of this review is to explore interactions between physicians and the pharmaceutical industry including sales representatives and their impact on physicians' attitude and prescribing habits.PubMed, Embase, Cochrane Library and Google scholar electronic databases were searched (...) industry and pharmaceutical sales representative (PSR) interactions influence physicians' attitudes and their prescribing behaviour and increase the number of formulary addition requests for the company's drug.Physician-pharmaceutical industry and its sales representative's interactions and acceptance of gifts from the company's PSRs have been found to affect physicians' prescribing behaviour and are likely to contribute to irrational prescribing of the company's drug. Therefore, intervention

Full Text available with Trip Pro

2017 BMJ open

9. [IBENTO][IBENTO]Report of the PMDA-ATC Pharmaceuticals Review Seminar 2017 in Bangkok, Thailand

of the seminar, the Course completion certificates were handed to each participant by Dr. Junko Sato. Photos and participant comments Lectures were provided by experts of product review, relief services and drug safety. There were also presentations by representatives from Sri Lanka and Thailand about their own pharmaceuticals review systems and regulations. Participants enthusiastically asked many questions and all the lecturers answered those questions. Comments from the participants: “I have (...) [IBENTO][IBENTO]Report of the PMDA-ATC Pharmaceuticals Review Seminar 2017 in Bangkok, Thailand Report of the PMDA-ATC Pharmaceuticals Review Seminar 2017 in Bangkok, Thailand | Pharmaceuticals and Medical Devices Agency Please make JavaScript on and see this site. Navigation of each product type Our recommended contents Navigation of each product type Our recommended contents Report of the PMDA-ATC Pharmaceuticals Review Seminar 2017 in Bangkok, Thailand Here begins the text. Report

2018 Pharmaceuticals and Medical Devices Agency, Japan

10. [IBENTO][IBENTO]Report of the PMDA-ATC Pharmaceuticals Review Seminar 2018 in Nay Pyi Taw, Myanmar

[IBENTO][IBENTO]Report of the PMDA-ATC Pharmaceuticals Review Seminar 2018 in Nay Pyi Taw, Myanmar Report of the PMDA-ATC Pharmaceuticals Review Seminar 2018 in Nay Pyi Taw, Myanmar | Pharmaceuticals and Medical Devices Agency Please make JavaScript on and see this site. Navigation of each product type Our recommended contents Navigation of each product type Our recommended contents Report of the PMDA-ATC Pharmaceuticals Review Seminar 2018 in Nay Pyi Taw, Myanmar Here begins the text. Report (...) of the PMDA-ATC Pharmaceuticals Review Seminar 2018 in Nay Pyi Taw, Myanmar PMDA-ATC Pharmaceuticals Review Seminar 2018 in Nay Pyi Taw, Myanmar Pharmaceuticals and Medical Devices Agency (PMDA) recently completed the PMDA-Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) Pharmaceuticals Review Seminar 2018 in Nay Pyi Taw, Myanmar on October 15 - 16, 2018. This seminar was designed for pharmaceuticals reviewers from Myanmar FDA. Total of 32 regulators from 3

2018 Pharmaceuticals and Medical Devices Agency, Japan

11. Physicians-Pharmaceutical Sales Representatives Interactions and Conflict of Interest: Challenges and Solutions (PubMed)

Physicians-Pharmaceutical Sales Representatives Interactions and Conflict of Interest: Challenges and Solutions Physician-industry relationships have come a long way since serious debates began after a 1990 Senate Committee on Labor and Human Resources report on the topic. On one side, the Sun Shine Act of 2007, now a part of the Patient Protection and Affordable Care Act that mandates disclosure of payments and gifts to the physicians, has injected more transparency into the relationships (...) , and on the other side, numerous voluntary self-regulation guidelines have been instituted to protect patients. However, despite these commendable efforts, problem persists. Taking the specific case of physician-pharmaceutical sales representative (PSR) interactions, also called as detailing, where the PSRs lobby physicians to prescribe their brand drugs while bringing them gifts on the side, an August 2016 article concluded that gifts as small as $20 are associated with higher prescribing rates. A close

Full Text available with Trip Pro

2016 Inquiry : a journal of medical care organization, provision and financing

12. Medical Representatives' Intention to Use Information Technology in Pharmaceutical Marketing (PubMed)

Medical Representatives' Intention to Use Information Technology in Pharmaceutical Marketing Electronic detailing (e-detailing), the use of electronic devices to facilitate sales presentations to physicians, has been adopted and expanded in the pharmaceutical industry. To maximize the potential outcome of e-detailing, it is important to understand medical representatives (MRs)' behavior and attitude to e-detailing. This study investigates how information technology devices such as laptop (...) computers and tablet PCs are utilized in pharmaceutical marketing, and it analyzes the factors influencing MRs' intention to use devices.This study has adopted and modified the theory of Roger's diffusion of innovation model and the technology acceptance model. To test the model empirically, a questionnaire survey was conducted with 221 MRs who were working in three multinational or eleven domestic pharmaceutical companies in Korea.Overall, 28% and 35% of MRs experienced using laptop computers

Full Text available with Trip Pro

2016 Healthcare informatics research

13. Pharmaceutical Representative

Pharmaceutical Representative Pharmaceutical Representative Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pharmaceutical (...) Representative Pharmaceutical Representative Aka: Pharmaceutical Representative , Drug Rep , Prescribing Cost , Sunshine Act From Related Chapters II. Research: Studies Evaluation of 446 physicians surveyed Higher Prescribing Cost risks Pharmaceutical Representative exposure Group practice setting References Direct drug advertising to healthcare consumers Appears to increase sale of drugs May result in inappropriate prescribing practices Pharmaceutical samples raise overall Prescribing Costs Poorest patients

2018 FP Notebook

14. Pharmaceutical Representatives

Pharmaceutical Representatives Pharmaceutical Representatives Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Pharmaceutical (...) Representatives Pharmaceutical Representatives Aka: Pharmaceutical Representatives , Drug Rep , Prescribing Cost , Sunshine Act From Related Chapters II. Research: Studies Evaluation of 446 physicians surveyed Higher Prescribing Cost risks Pharmaceutical representative exposure Group practice setting References Direct drug advertising to healthcare consumers Appears to increase sale of drugs May result in appropriate prescribing practices Pharmaceutical samples raise overall Prescribing Costs Poorest patients

2018 FP Notebook

15. Interaction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesis (PubMed)

Interaction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesis It has been proven that the interaction between pharmaceutical representatives and physicians can directly influence the latter's prescribing behaviour. This meta-synthesis aims to explore the available studies regarding the nature of the interaction that takes place between pharmaceutical representatives and physicians. It highlights the different aspects of that interaction (...) , the United Kingdom, Yemen, and Japan. Six main themes were derived from the included articles: 1-the frequency of pharmaceutical representatives' visits, 2-the perceived ethical acceptability of the interactions between pharmaceutical representatives and physicians, 3-the attitudes held by physicians towards visits by pharmaceutical representatives, 4-their perception of the effect of such visits on prescription patterns, 5-reasons to accept or reject pharmaceutical representatives, and lastly, 6

Full Text available with Trip Pro

2016 Journal of pharmaceutical policy and practice

16. Good Psychiatric Practice: Relationships with pharmaceutical and other related organisations

Good Psychiatric Practice: Relationships with pharmaceutical and other related organisations Good Psychiatric Practice- Relationships with pharmaceutical and other related organisations (CR202 Mar 2017) This site uses cookies: Search Search Become a psychiatrist Choose psychiatry Medical students Foundation doctors Help us promote psychiatry Training Curricula and guidance Your training Exams Neuroscience in training International Medical Graduates Members Supporting you Submitting your CPD (...) Psychiatric Practice: Relationships with pharmaceutical and other related organisations (CR202 Mar 2017) Good Psychiatric Practice (CR202 Mar 2017) This report provides guidance to those interacting or working with commercial organisations, including the pharmaceutical industry, on behalf of the Royal College of Psychiatrists. The guidance applies mainly to competing interests but also includes advice on maintaining boundaries and clarity of roles. All psychiatrists must follow the guidance and standards

2018 Royal College of Psychiatrists

17. Pharmaceutical research and development: a new system is needed

; requiring proof that new drugs represent a therapeutic advance before granting marketing authorisation; and demanding transparency over the costs of pharmaceutical R&D and drug pricing. In the long term, a global mechanism would need to be established, which would include: providing the public funds necessary to support needs-driven approach to pharmaceutical R&D; establishing new methods that "delink" R&D costs from the end price of health products to make them affordable; and creating a global (...) Pharmaceutical research and development: a new system is needed Prescrire IN ENGLISH - Spotlight ''Pharmaceutical research and development: a new system is needed'', 1 May 2017 {1} {1} {1} | | > > > Pharmaceutical research and development: a new system is needed Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pharmaceutical research

2017 Prescrire

18. Buprenorphine-Naloxone (Suboxone) for Pharmaceutical Opioid Use Disorder

Buprenorphine-Naloxone (Suboxone) for Pharmaceutical Opioid Use Disorder Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family practice through advocacy, continuing medical education and primary care research (...) . www.acfp.ca November 5, 2018 Buprenorphine-Naloxone (Suboxone ? ) for Pharmaceutical Opioid Use Disorder Clinical Question: Is buprenorphine (with or without naloxone) effective as maintenance therapy in pharmaceutical opioid use disorder? Bottom Line: Retention in treatment at 15 weeks was seen in 75% taking buprenorphine compared to 26% in detoxification and/or counselling, with 37% reporting ongoing substance use compared to 60% in control. Outcomes between buprenorphine and methadone

2018 Tools for Practice

19. Pharmaceutical marketing: the harmful influence of pharmaceutical reps' visits on prescriptions

reps' visits sidetrack healthcare professionals from their fundamental objective: to offer patients the most appropriate treatments. Another reason for doctors to follow the example of the 17% of GPs questioned who refuse to see pharmaceutical reps. ©Prescrire 1 October 2013 Download the full review. For more information: Pharmaceutical sales representatives: no hopes for improved care (June 2006) The French medical sales charter: ineffective Prescrire Int 2010 ; 19 (109) : 235. Pharmaceutical (...) Pharmaceutical marketing: the harmful influence of pharmaceutical reps' visits on prescriptions Prescrire IN ENGLISH - Spotlight ''Pharmaceutical marketing: the harmful influence of pharmaceutical reps' visits on prescriptions'', 1 October 2013 {1} {1} {1} | | > > > Pharmaceutical marketing: the harmful influence of pharmaceutical reps' visits on prescriptions Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   

2013 Prescrire

20. Pharmaceuticals Requiring Companion Diagnostics

. With respect to a collaborative model, the availability of internal diagnostics divisions within pharmaceutical manufacturers — such as at Roche, Abbott, and Novartis — does not as yet appear to represent a more favourable structure than the use of external diagnostics providers — such as at GlaxoSmithKline, Pfizer, or AstraZeneca. 47 Of note, an increase in the number of co-development and partnership agreements between pharmaceutical and diagnostic manufacturers was reported in recent years. It was found (...) Pharmaceuticals Requiring Companion Diagnostics Pharmaceuticals Requiring Companion Diagnostics | CADTH.ca CADTH Document Viewer Pharmaceuticals Requiring Companion Diagnostics Table of Contents Search this document Pharmaceuticals Requiring Companion Diagnostics June 2016 Background and Context The purpose of this Environmental Scan is to provide an overview of the current and projected use of companion diagnostic tests required for the prescription of targeted drug therapies, as well

2016 Canadian Agency for Drugs and Technologies in Health - Environmental Scanning

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>